Buntanetap for Early Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new pill called buntanetap/posiphen to help people with early Parkinson's Disease. The pill aims to reduce brain inflammation and protect nerve cells, which could improve movement and daily activities. The study will compare the effects of the pill over several months.
Will I have to stop taking my current medications?
The trial does not specify that you must stop taking your current medications. However, you need to have stable medications for at least 4 weeks before screening, and certain medications like CYP3A4 inhibitors or inducers are not allowed.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily administration of 10 mg or 20 mg of buntanetap/posiphen or placebo for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including a 24-hour follow-up call after each clinical visit
What Are the Treatments Tested in This Trial?
Interventions
- Buntanetap
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Annovis Bio Inc.
Lead Sponsor
TFS Trial Form Support
Industry Sponsor